Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

about

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

Item

http://www.wikidata.org/entity/Q38934396

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

@en

type

Item

label

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

@en

prefLabel

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

@en

P1476

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

@en

P2093

Dan Mikol

http://www.w3.org/2001/XMLSchema#string

Deb Steiner

http://www.w3.org/2001/XMLSchema#string

Diogo Amarante

http://www.w3.org/2001/XMLSchema#string

Ivan Nestorov

http://www.w3.org/2001/XMLSchema#string

Jacob Elkins

http://www.w3.org/2001/XMLSchema#string

Kumar Kandadi Muralidharan

http://www.w3.org/2001/XMLSchema#string

Meena Subramanyam

http://www.w3.org/2001/XMLSchema#string

Pei-Ran Ho

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Modeling and simulation of count data.

Application of hidden Markov models to multiple sclerosis lesion count data.

Extended interval dosing of natalizumab in multiple sclerosis.

Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach.

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

A longitudinal model for magnetic resonance imaging lesion count data in multiple sclerosis patients.

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

P2888

s10928-017-9514-4

P304

263-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10928-017-9514-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084028043

http://www.w3.org/2001/XMLSchema#string

P698

28251386

http://www.w3.org/2001/XMLSchema#string